Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IN-VIVO IMAGING OF PITUITARY-TUMORS USING A RADIOLABELED DOPAMINE D2 RECEPTOR RADIOLIGAND
Autore:
DEHERDER WW; REIJS AEM; KWEKKEBOOM DJ; HOFLAND LJ; NOBELS FRE; OEI HY; KRENNING EP; LAMBERTS SWJ;
Indirizzi:
UNIV ROTTERDAM HOSP,DEPT INTERNAL MED 3,DR MOLEWATERPLEIN 40 NL-3015 GD ROTTERDAM NETHERLANDS UNIV ROTTERDAM HOSP,DEPT NUCL MED ROTTERDAM NETHERLANDS
Titolo Testata:
Clinical endocrinology
fascicolo: 6, volume: 45, anno: 1996,
pagine: 755 - 767
SICI:
0300-0664(1996)45:6<755:IIOPUA>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-HORMONE; ALPHA-SUBUNIT; ADENOMAS; BROMOCRIPTINE; PROLACTINOMAS; GONADOTROPH; AGONISTS; VISUALIZATION; BINDING; RELEASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
29
Recensione:
Indirizzi per estratti:
Citazione:
W.W. Deherder et al., "IN-VIVO IMAGING OF PITUITARY-TUMORS USING A RADIOLABELED DOPAMINE D2 RECEPTOR RADIOLIGAND", Clinical endocrinology, 45(6), 1996, pp. 755-767

Abstract

OBJECTIVE Knowledge of the dopamine D2 receptor status of pituitary tumours may play a predictive role in differential diagnosis and therapeutic decisions. This study was performed to evaluate the value of pituitary dopamine D2 receptor scintigraphy with ethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide (I-123-IBZM) in the diagnostic evaluation of patients with pituitary tumours. DESIGN AND PATIENTS Scintigraphy using I-123-IBZM was performed in 5 patients with PRL-secreting macroadenomas, 2 patients with PRL-secreting microadenomas, 17 patients with clinically nonfunctioning pituitary adenomas (NFPAs), 12 patients with GH-secreting adenomas and 1 patient with a TSH-secreting macroadenoma. RESULTS Single-photon emission tomography (SPECT) showed significant uptake of I-123-IBZM in the pituitary region in 3/5 macroprolactinoma patients. These results closely correlated with the response of plasmaPRL levels to the dopamine D2 receptor agonist quinagolide. In two scan-positive prolactinoma patients, repeated SPECTs during therapy withquinagolide showed a reduction in the pituitary uptake of I-123-IBZM. Pituitary SPECT was negative in the 2 microprolactinoma patients, whoresponded to quinagolide administration. In 4/17 patients with NFPA, significant uptake of the radioligand in the pituitary region was observed. In 2/3 scan-positive NFPA patients, who were treated with quinagolide, shrinkage of the pituitary tumours was observed. Treatment withquinagolide resulted in stabilization of tumour growth in the other scan-positive patients. Four out of 17 patients with NFPA and a negative SPECT were treated with quinagolide. Tumour growth was observed in 1patient, and tumour size did not change in the other 3 patients. The pituitary region of none of the 12 acromegaly patients showed significant uptake of I-123-IBZM. Sensitivity of the GH-secreting adenomas to quinagolide was demonstrated in 8/12 patients in vivo by an acute test, and in 6/9 of the tumours in vitro. Pituitary SPECT was negative in the patient with the TSH-secreting macroadenoma and this tumour also showed no sensitivity to quinagolide in vivo or in vitro. CONCLUSIONS We conclude that I-123-IBZM is a ligand for in vivo imaging of dopamineagonist- sensitive macroprolactinomas, but not for microprolactinomasor GH-secreting adenomas. The technique potentially provides a means of predicting the dopamine agonist-responses of non-functioning pituitary adenomas in vivo.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 01:10:34